Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arterra Bioscience SpA ( (IT:ARBS) ) has issued an announcement.
Arterra Bioscience S.p.A. reported preliminary 2025 revenues of approximately €4.6 million, up 11.42% year on year, driven mainly by the sale of cosmetic raw materials. Revenue from cosmetic ingredients rose 12.62% to about €4.0 million, while service revenues increased 4.94% to roughly €0.7 million, underscoring stronger commercial traction in its core cosmetics business.
Management said the results align with the company’s commercial development plans for cosmetic raw materials and noted that early 2026 figures support an optimistic outlook for the current year. The sustained growth in high-value cosmetic ingredients reinforces Arterra’s positioning in the specialty cosmetics supply chain and signals ongoing momentum for partners and investors focused on bio-sustainable beauty technologies.
More about Arterra Bioscience SpA
Arterra Bioscience S.p.A. is an Italian green biotech company focused on biotechnology research and development, applying living organisms such as bacteria, yeasts, and plant and animal cells to create enabling technologies. Its products and processes serve multiple sectors, including cosmetics, agriculture, and nutraceuticals, supported by long-term collaborations with partners like Intercos and Isagro.
Listed on Euronext Growth Milan since 2019, the Naples-based company has built a significant presence in cosmetic ingredients through Vitalab, a joint venture with Intercos dedicated to innovative skin care, personal hygiene, and functional make-up products. Arterra’s model combines proprietary R&D with industrial partnerships to advance bio-sustainable solutions across its target markets.
Average Trading Volume: 20,542
Technical Sentiment Signal: Buy
Current Market Cap: €21.57M
For detailed information about ARBS stock, go to TipRanks’ Stock Analysis page.